Výsledky vyhledávání - "T.C. Hernandez-Guerrero"

8MO CC-90010, a reversible, potent oral bromodomain and extraterminal inhibitor (BETi) in patients (pts) with advanced solid tumours (aSTs) and relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): Longer follow-up from parts A & B and first reporting of part C of a phase I study

Publikováno v: Annals of Oncology. 32:S5

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::b224a91543680d4f2a7947adfa5f0ebe
https://doi.org/10.1016/j.annonc.2021.01.021

Zobrazit plný text záznamu

560P Safety and efficacy of Debio 1143, an antagonist of inhibitor of apoptosis proteins (IAPs), in combination with nivolumab in a phase Ib/II trial in patients (pts) failing prior PD-1/PD-L1 treatment

Autor: T.C. Hernandez Guerrero, E. Roy, Carlos Gomez-Roca, I. Korakis, Eva Calvo, C. Riff, P. A. Cassier, A.B. Azaro Pedrazzoli, Kathrin Gollmer, Victor Moreno, D. Purcea, Sergio Szyldergemajn, M.J. de Miguel, Caroline Even

Publikováno v: Annals of Oncology. 31:S483

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::73cef2f3d95b4663e5ccf185a4822202
https://doi.org/10.1016/j.annonc.2020.08.674

Zobrazit plný text záznamu

1025MO First-in-human (FIH) phase I study of RO7122290 (RO), a novel FAP-targeted 4-1BB agonist, administered as single agent and in combination with atezolizumab (ATZ) to patients with advanced solid tumours

Publikováno v: Annals of Oncology. 31:S707

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::fcdea892f2e9927524b8be4b3dceeabe
https://doi.org/10.1016/j.annonc.2020.08.1145

Zobrazit plný text záznamu

16O Phase I study of CC-90010, a reversible, oral BET inhibitor in patients (Pts) with advanced solid tumors (STs) and relapsed/refractory non-Hodgkin lymphoma (R/R NHL)

Publikováno v: Annals of Oncology. 31:S5

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::88d79aff59bada26f44113db50e9b264
https://doi.org/10.1016/j.annonc.2020.01.025

Zobrazit plný text záznamu

Early Phase Clinical Trial Designs - State of Play and Adapting for the Future

Autor: J.A. Harrington, Bristi Basu, T.C. Hernandez-Guerrero

Publikováno v: Clinical oncology (Royal College of Radiologists (Great Britain)). 29(12)

The process of anti-cancer drug development is complex, with high attrition rates. Factors that may optimise this process include well-constructed and relevant pre-clinical testing and use of biomarkers for patient selection. However, the design of e

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9b1b79447be58587e40cfca74f22a7fb
https://pubmed.ncbi.nlm.nih.gov/29108786

Zobrazit plný text záznamu

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Vyhledávací nástroje:

Upřesnit hledání